IDT

73.7201.56%
WC

William Conkling

Independent Director

Mr. William Conkling, also known as Bill, has been Chief Commercial Officer of Protara Therapeutics, Inc. since June 2, 2025. He is Independent Director of IDT Corporation from June 2026. He is Independent Director at Cyclo Therapeutics, Inc. from May 02, 2023. He serves as Director at LipoMedix Pharmaceutical Inc. since 2024. He served as Chief Commercial Officer at Rafael Holdings, Inc., since March 15, 2021 until November 10, 2021. He was Chief Commercial and Business Officer as at Rafael Holdings, Inc., since November 10, 2021 until February 01, 2022. He was Chief Executive Officer of Rafael Holdings, Inc since February 01, 2022 until 2025 and also served as its President. He has experience specializing in the development and commercialization of novel cancer therapeutics. Mr. Conkling spent with Novartis Oncology where he held key leadership roles in the development and commercialization of several oncology products, including Kymriah, the first CAR-T therapy approved in the US. He has had a career specializing in the commercialization of cancer therapeutics. He was Vice President Sales, Marketing, Market Access and Commercial Operations at Immunomedics. Prior to joining Immunomedics, Mr. Conkling was Vice President, Commercial and Head of CAR-T at Novartis. Mr. Conkling has experience in the pharmaceutical/biotech industry working in Oncology. Mr. Conkling helped lead the launch of Trodelvy at Immunomedics Inc. as the VP Sales, Marketing and Market Access. Mr. Conkling holds an MBA from New York University's Stern School of Business in 1998 and a B.S. from Fordham University.

Positions